Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
